首页> 外文期刊>药物分析学报(英文) >Liquid chromatography-tandem mass spectrometry method for the estimation of adefovir in human plasma:Application to a pharmacokinetic study
【24h】

Liquid chromatography-tandem mass spectrometry method for the estimation of adefovir in human plasma:Application to a pharmacokinetic study

机译:液相色谱-串联质谱法估算人血浆中阿德福韦:在药代动力学研究中的应用

获取原文
获取原文并翻译 | 示例
       

摘要

An analytical method based on solid phase extraction was developed and validated for analysis of adefovir in human plasma. Adefovir-d4 was used as an internal standard and Synergi MAX RP80A (150 mm × 4.6 mm, 4μm) column provided the desired chromatographic separation of compounds followed by detection with mass spectrometry. The method used simple isocratic chromato-graphic condition and mass spectrometric detection in the positive ionization mode. The calibration curves were linear over the range of 0.50–42.47 ng/mL with the lower limit of quantitation validated at 0.50 ng/mL. Matrix effect was assessed by post-column infusion experiment to monitor phospholipids and post-extraction addition experiment was performed. The degree of matrix effect for adefovir was determined as 7.5%and ion-enhancement in five different lots of human plasma was 7.1%and had no impact on study samples analysis with 4.5 min run time. The intra- and inter-day precision values were within 7.7% and 7.8%, respectively, for adefovir at the lower limit of quantification level. Validated bioanalytical method was successfully applied to clinical sample analysis.
机译:开发了一种基于固相萃取的分析方法,并验证了该方法可用于分析人血浆中的阿德福韦。阿德福韦-d4用作内标,Synergi MAX RP80A(150 mm×4.6 mm,4μm)色谱柱提供所需的化合物色谱分离,然后通过质谱检测。该方法使用简单的等度色谱条件,并在正电离模式下进行质谱检测。校准曲线在0.50–42.47 ng / mL范围内呈线性,定量下限为0.50 ng / mL。通过柱后输注实验评估基质作用以监测磷脂,并进行提取后添加实验。确定阿德福韦的基质效应程度为7.5%,五个不同批次的人类血浆中的离子增强度为7.1%,并且对4.5分钟运行时间的研究样品分析没有影响。在定量水平的下限,阿德福韦的日内和日间精密度值分别在7.7%和7.8%之内。经验证的生物分析方法已成功应用于临床样品分析。

著录项

  • 来源
    《药物分析学报(英文)》 |2015年第003期|190-199|共10页
  • 作者单位

    Sun Pharmaceutical industries Ltd., Plot No. GP-5, Sector-18, Gurgaon-122015, Haryana, India;

    Department of Clinical Pharmacology and Pharmacokinetics, Ranbaxy Laboratories, Ltd., HSIDC, GP-5, 0ld Delhi Gurgaon Road, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India;

    Department of Clinical Pharmacology and Pharmacokinetics, Ranbaxy Laboratories, Ltd., HSIDC, GP-5, 0ld Delhi Gurgaon Road, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India;

    Department of Clinical Pharmacology and Pharmacokinetics, Ranbaxy Laboratories, Ltd., HSIDC, GP-5, 0ld Delhi Gurgaon Road, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India;

    Department of Clinical Pharmacology and Pharmacokinetics, Ranbaxy Laboratories, Ltd., HSIDC, GP-5, 0ld Delhi Gurgaon Road, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India;

    Department of Clinical Pharmacology and Pharmacokinetics, Ranbaxy Laboratories, Ltd., HSIDC, GP-5, 0ld Delhi Gurgaon Road, Udyog Vihar Industrial Area, Gurgaon 122 015, Haryana, India;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 03:45:45
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号